-
Snowstorm blankets US northeast as New York sees travel ban
-
Healthcare crisis looms over Greenland's isolated villages
-
Hodgkinson says breaking 800m record would put her among athletics' greatest
-
Two Russian security personnel were on board France-seized tanker: sources
-
EU puts US trade deal on ice after Supreme Court ruling
-
Hetmyer blasts 85 as West Indies pile up 254-6 against Zimbabwe
-
Canada PM heads to Asia seeking new trade partners as US ties fray
-
South Africa accepts Trump's new US ambassador
-
Iraq's Maliki defends PM candidacy, seeks to reassure US
-
UEFA suspend Benfica's Prestianni after alleged racist abuse
-
Jetten sworn in as youngest-ever Dutch PM
-
Italy's Enel to invest 20bn euros in renewables by 2028
-
BBC apologises for 'involuntary' Tourette's racial slur during BAFTA awards
-
Kristen Bell returns to host glitzy Actor Awards in Hollywood
-
Iran says would respond 'ferociously' to any US attack
-
Venezuelan foreign minister demands 'immediate release' of Maduro
-
Dane Vingegaard to start season at Paris-Nice in March
-
Australia PM backs removing UK's Andrew from line of succession
-
Where do Ukraine and Russia stand after four years of war?
-
Police investigating racist abuse of Premier League quartet
-
Fiji to start Nations Championship at 'home' to Wales in Cardiff
-
EU lawmakers to put US trade deal on hold after Supreme Court ruling
-
Rubio to attend Caribbean summit as US presses Venezuela, Cuba
-
'Ugly' England aim to spin their way to T20 World Cup semi-finals
-
Nigeria paid Boko Haram ransom for kidnapped pupils: intel sources
-
Tudor says Tottenham can still beat the drop despite Arsenal loss
-
Violence sweeps Mexico after most-wanted drug cartel leader killed
-
France giant Meafou capable of being 'world's best' lock
-
Stocks diverge, dollar down over Trump tariffs uncertainty
-
World champions South Africa announce eight home Tests for 2026/27
-
Liverpool boss Slot encouraged by Mac Allister's return to form
-
India replaces British architect statue with independence hero
-
Pakistan warn England's flaky batting to expect a trial by spin
-
Philippines' Duterte authorised murders, ICC told as hearings open
-
Iran says would respond 'ferociously' to any US attack, even limited strikes
-
New Dutch government sworn in under centrist Jetten
-
What the future holds for the CJNG cartel after leader killed
-
ICC kicks off pre-trial hearing over Philippines' Duterte
-
UN chief decries global rise of 'rule of force'
-
Nemesio Oseguera, the brutal Mexican drug lord known as 'El Mencho'
-
Senegal's Sahad, radiant champion of 'musical pan-Africanism'
-
New York orders citywide travel ban as major storm hits US
-
'Considered a traitor': Life of an anti-war Ukrainian in Russia
-
South Korea and Brazil sign deals on K-beauty, trade
-
Zimbabwe farmers seek US help over long-promised payouts
-
Hong Kong appeals court upholds jailing of 12 democracy campaigners
-
India battle for World Cup survival after 'messing up on grand scale'
-
'I will go': Bengalis in Pakistan hope for family reunions
-
North Korea touts nuclear advances as Kim re-chosen to lead ruling party
-
South Korea protests 'Victory' banner hung from Russian embassy
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
L.AbuAli--SF-PST